Semaglutide in Obesity: Unmet Needs in Men
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Gender-specific issues in weight management with semaglutide need to be addressed to maximize the benefits of this agent to patients. Global average data suggest that the prevalence of male obesity is increasing and that its prevalence in some regions of Western Europe, Japan, China, Korea and USA is higher than that of female obesity [1]. However, men appear reluctant to engage in weight loss intervention programs despite verified established links between obesity and health-related diseases [2]. This reticence may reflect a general failure to recognize gender issues in weight management. A novel second-generation anti-obesity pharmacotherapy strategy against obesity represents a considerable advance in the efficacy of obesity management programs, as well as a significant change in the treatment of obesity [3]. The Semaglutide Treatment Effect in People with Obesity (STEP) Phase 3a clinical development program evaluated the safety and efficacy of the first second-generation medication, namely semaglutide, administered subcutaneously once weekly, for weight management in adults with obesity or overweight with at least one weight-related comorbidity [4–7]. STEP 2 enrolled patients with overweight or obesity with type 2 diabetes (T2D), while the other STEP studies (STEP 1, 3 and 4) enrolled patients with overweight or obesity, without T2D [4–7]. In STEP 4, patients who reached and tolerated a maintenance dose of semaglutide 2.4 mg during a 20-week run-in period were randomized at week 20 to continue semaglutide or switch to placebo [7]. M. Jensterle A. Janež (&) Department of Endocrinology, Diabetes and Metabolic Disease, University Medical Centre Ljubljana, Zaloska 7, 1000 Ljubljana, Slovenia e-mail: andrej.janez@kclj.si
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Once-weekly semaglutide in adolescents with obesity
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208601 · Cited by 730 · cited 2×
“This higher frequency of GIAEs in women could be partially attributed to higher drug exposures, yet the findings of an exposure– response analysis of semaglutide demonstrated that GI-AEs were more frequent in women also across different levels of exposure and that they were not exclusively related to drug concentratio…”
ResultSex differences in the physiology of eating
Asarian, L., & Geary, N. (2013) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00446.2012 · Cited by 513
Nauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care · doi:10.2337/dc15-0165 · Cited by 233
Jensterle, M., Rizzo, M., Haluzík, M., & Janež, A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02153-x · Cited by 215 · cited 1×
“A novel second-generation anti-obesity pharmacotherapy strategy against obesity represents a considerable advance in the efficacy of obesity management programs, as well as a significant change in the treatment of obesity [3].”
BackgroundSelf-citationRentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140
Effects of liraglutide on obesity-associated functional hypogonadism in men
Jensterle, M., Podbregar, A., Goricar, K., Gregoric, N., & Janez, A. (2019) · Endocrine Connections · doi:10.1530/ec-18-0514 · Cited by 101
Self-citationVogel, H., Wolf, S., Rabasa, C., Rodriguez-Pacheco, F., Babaei, C. S., Stöber, F., Goldschmidt, J., DiMarchi, R. D., Finan, B., Tschöp, M. H., et al. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.039 · Cited by 86
Research works printed but not linked: 9
- Dombrowski SU, McDonald M, van der Pol M, Grindle M, et al. Game of Stones: feasibility randomised controlled trial of how to engage men with obesity in text message and incentive interventions for weight loss. BMJ Open. 2020;10(2): e032653. · DOI
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414–25. · DOI · Paper page
- Overgaard RV, Petri KCC, Jacobsen LV, Jensen CB. Liraglutide 3.0 mg for weight management: a population pharmacokinetic analysis. Clin Pharmacokinet. 2016;55:1413–22. · DOI · Paper page
- Kerstetter KA, Ballis MA, Duffin-Lutgen S, Carr AE, Behrens AM, Kippin TE. Sex differences in selecting between food and cocaine reinforcement are mediated by estrogen. Neuropsychopharmacology. 2012;37:2605–14. · DOI
- Park MI, Camilleri M. Gastric motor and sensory functions in obesity. Obes Res. 2005;13:491–500. · DOI · Paper page
- Kim DY, Camilleri M, Murray JA, Stephens DA, Levine JA, Burton DD. Is there a role for gastric accommodation and satiety in asymptomatic obese people? Obes Res. 2020;9:655–61. · DOI
- Camilleri M, Iturrino J, Bharucha AE, et al. Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants. Neurogastroenterol Motil. 2012;24:1076-e562. · DOI · Paper page
- Kapitza C, Lynge J, Düring M, Jensen C. Safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD) of single escalating doses of semaglutide, a unique once weekly GLP-1 analogue, in healthy male subjects. Diabetologia. 2012;55:S1–538.
- Janez A, Muzurovic E, Stoian AP, et al. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: recommendations from a Eastern and Southern Europe diabetes expert group. Int J Cardiol. 2022;365:8–18. · DOI
Cited by
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice
Gasoyan, H., Pfoh, E. R., Schulte, R., Le, P., Butsch, W. S., & Rothberg, M. B. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.33326 · Cited by 71
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Milani, I., Chinucci, M., Leonetti, F., & Capoccia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13040855 · Cited by 38
“This supports the likely role of sex hormones in the regulation of eating behavior mediated by GLP1-RAs [341].”
Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30
Maselli, D. B., Lee, D., Bi, D., Jirapinyo, P., Thompson, C. C., Donnangelo, L. L., & McGowan, C. E. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07278-2 · Cited by 28
“…to men; however, this ratio is consistent with sex-based differences in obesity diagnosis and care-seeking, including for ESG and GLP1-RAs [9, 31, 32], and women are possibly more likely to be at risk for adverse events related to gastric emptying delays from GLP1-RAs, as they have slower…”
Metadata
- Authors
- Jensterle, M., Rizzo, M., & Janež, A.
- Venue
- Diabetes Therapy
- Published
- 2023-01-07
- Volume
- 14
- Issue
- 3
- Pages
- 461-465
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- OpenAlex
- W4313656426
- Cited by
- 36
- References
- 13
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Semaglutide in Obesity: Unmet Needs in Men. https://app.cochat.ai/papers/10.1007/s13300-022-01360-7
- The paper
- Jensterle, M., Rizzo, M., & Janež, A. (2023). Semaglutide in Obesity: Unmet Needs in Men. Diabetes Therapy. https://doi.org/10.1007/s13300-022-01360-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.